Literature DB >> 5212354

Long-term propranolol therapy in muscular subaortic stenosis.

A G Adelman, P M Shah, R Gramiak, E D Wigle.   

Abstract

Twenty-one patients with muscular subaortic stenosis were treated with oral propranolol for periods of 6 to 34 months for a total of 42.5 patient years. The average follow-up was 2 years. Four patients with latent obstruction became asymptomatic on propranolol therapy. Of the 17 patients with resting obstruction, 7 improved, 2 were unchanged, 5 deteriorated, and 2 died during the period of treatment. The 7 patients with resting obstruction who are still improved on propranolol have had relatively short periods of treatment (average 15 months), and none experienced the degree of improvement that occurred in the patients with latent obstruction. This study indicates that propranolol is most effective in patients with muscular subaortic stenosis who have latent obstruction. It is of limited value in patients with resting obstruction because the benefit of propranolol therapy in the majority of these patients is eventually overtaken by progression in the disease.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5212354      PMCID: PMC487418          DOI: 10.1136/hrt.32.6.804

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  19 in total

1.  EFFECT OF LEFT VENTRICULAR SIZE AND SHAPE UPON THE HEMODYNAMICS OF SUBAORTIC STENOSIS.

Authors:  M D KLEIN; F J LANE; R GORLIN
Journal:  Am J Cardiol       Date:  1965-06       Impact factor: 2.778

2.  Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol.

Authors:  M D Flamm; D C Harrison; E W Hancock
Journal:  Circulation       Date:  1968-11       Impact factor: 29.690

3.  Operative treatment in idiopathic hypertrophic subaortic stenosis. Techniques, and the results of preoperative and postoperative clinical and hemodynamic assessments.

Authors:  A G Morrow; T J Fogarty; H Hannah; E Braunwald
Journal:  Circulation       Date:  1968-04       Impact factor: 29.690

4.  Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history.

Authors:  S Frank; E Braunwald
Journal:  Circulation       Date:  1968-05       Impact factor: 29.690

5.  The ventriculomyotomy operation for muscular subaortic stenosis. A reappraisal.

Authors:  W G Bigelow; A S Trimble; P Auger; Y Marquis; E D Wigle
Journal:  J Thorac Cardiovasc Surg       Date:  1966-10       Impact factor: 5.209

6.  Idiopathic hypertrophic subaortic stenosis. Effects of changes in heart rate on the severity of obstruction to left ventricular outflow.

Authors:  D T Mason; L H Cohn; J Ross; E Braunwald
Journal:  Am J Cardiol       Date:  1967-06       Impact factor: 2.778

7.  The course in idiopathic hypertrophic muscular subaortic stenosis.

Authors:  B M Parker
Journal:  Ann Intern Med       Date:  1969-05       Impact factor: 25.391

8.  Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade.

Authors:  L S Cohen; E Braunwald
Journal:  Circulation       Date:  1967-05       Impact factor: 29.690

9.  Propranolol in management of muscular subaortic stenosis.

Authors:  G Sloman
Journal:  Br Heart J       Date:  1967-09

10.  Muscular subaortic stenosis: the initial left ventricular inflow tract pressure as evidence of outflow tract obstruction.

Authors:  E D Wigle; P Auger; Y Marquis
Journal:  Can Med Assoc J       Date:  1966-10-15       Impact factor: 8.262

View more
  10 in total

1.  Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy.

Authors:  P J Hubner; G M Ziady; G K Lane; T Hardarson; B Scales; C M Oakley; J F Goodwin
Journal:  Br Heart J       Date:  1973-11

2.  Acute haemodynamic effects of practolol in patients with idiopathic hypertrophic subaortic stenosis.

Authors:  H J Matlof; D C Harrison
Journal:  Br Heart J       Date:  1973-02

Review 3.  Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Drugs       Date:  1974       Impact factor: 9.546

Review 4.  Beta-adrenergic receptor blocking drugs in hypertrophic cardiomyopathy, autonomically mediated cardiovascular functional disorders and Fallot's tetralogy.

Authors:  C D Furberg
Journal:  Drugs       Date:  1974       Impact factor: 9.546

5.  Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy.

Authors:  K Landmark; S Sire; E Thaulow; J P Amlie; S Nitter-Hauge
Journal:  Br Heart J       Date:  1982-07

Review 6.  Targeted Medical Therapies for Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Maria Grazia De Gregorio; Mattia Zampieri; Elisa Fedele; Alessia Tomberli; Chiara Chiriatti; Alberto Marchi; Iacopo Olivotto
Journal:  Curr Cardiol Rep       Date:  2020-01-28       Impact factor: 2.931

7.  Surgical management of hypertrophic cardiomyopathy in 2007: what is new?

Authors:  Morgan L Brown; Hartzell V Schaff
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

Review 8.  Hypertrophic cardiomyopathy: a review.

Authors:  Brian A Houston; Gerin R Stevens
Journal:  Clin Med Insights Cardiol       Date:  2015-01-26

Review 9.  Uses of beta-adrenoceptor blocking drugs.

Authors:  B N Prichard; D G McDevitt; R G Shanks
Journal:  J R Coll Physicians Lond       Date:  1976-10

10.  Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature.

Authors:  Ahmed M Abdel-Razek; Leonard Y Lee; Robert Tozzi
Journal:  Heart Views       Date:  2011-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.